Overview | Donepezil benzyl bromide hydrochloride is an intermediate for the synthesis of donepezil hydrochloride. Donepezil hydrochloride is a second-generation acetylcholinesterase inhibitor approved by the FDA for the treatment of Alzheimer's disease. It was successfully developed by Japan Eisai Pharmaceutical Co., Ltd. in 1989. It was approved by FDA in November 1996 for the treatment of Alzheimer's disease. It was first listed in the United States in January 1997 and in China in October 1999. Now it has been listed in more than 30 countries in the world. Its curative effect has been confirmed by clinical experiments in Britain, the United States, Japan and other countries. Donacia is a selective, reversible, non-competitive acetylcholinesterase inhibitor that inhibits the degradation of acetylcholinesterase by acetylcholinesterase and activates the central cholinergic system, thereby reducing the damage of cholinergic transmission. Neuronal degeneration. Donaaquil has a high degree of selectivity for acetylcholinesterase in neurons in the brain, but has no significant inhibitory effect on acetylcholinesterase in the digestive tract and heart. Compared with the first generation of acetylcholinesterase The inhibitor tacrine has the advantages of small dose (5-10mg), low side effects, long-acting (half-life of 70 hours, only once a day), and low cost. It is a more valuable drug for the treatment of mild and moderate AD. Recently, studies have found that Donecia is also effective for cerebrovascular dementia, further expanding the indications of the drug. |